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Large Artery Intracranial Occlusive Disease
A Large Worldwide Burden but a Relatively Neglected Frontier
Philip B. Gorelick, MD, MPH; Ka Sing Wong, MD;
Hee-Joon Bae, MD, PhD; Dilip K. Pandey, MD, PhD
Background and Purpose—Large artery intracranial occlusive disease (LAICOD) is a common and important stroke
subtype. In this commentary, we review key epidemiological aspects of LAICOD.
Summary of Review— LAICOD has emerged as the most common stroke subtype worldwide and is associated with a high
risk of recurrent stroke. Hypotheses have been proposed to explain causation, which include such factors as traditional
cardiovascular risk factors, high blood volume states, and genetic abnormalities. Approaches to treatment such as
antithrombotic therapies, revascularization procedures, and counterpulsation devices hold promise.
Conclusions—LAICOD poses a major stroke problem worldwide and is likely the most common stroke subtype. The
etiology and treatment of this disorder remain poorly defined. International collaborations are needed to pool collective
knowledge and develop definitive studies to better understand causation and treatment of LAICOD. (Stroke. 2008;39:
2396-2399.)
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Large artery intracranial occlusive disease (LAICOD) hasemerged as a well-defined stroke subtype.1,2 As a well-
defined and prevalent stroke subtype, LAICOD serves as an
important target for prevention and treatment. It had received
relatively little attention in the United States and North America,
however, until it became better known in the late 1950s and
1960s. This was based on a series of brain autopsy studies in the
south of the United States and the International Atherosclerosis
Project,3,4 conventional cerebral angiographic studies that we
carried out in the 1980s among a racially mixed, hospital,
referral-based population in Chicago, Ill,5–7 and the international
Extracranial-Intracranial Bypass Trial of the 1980s.8 More re-
cently, the importance of LAICOD has been highlighted by the
Warfarin-Aspirin Symptomatic Intracranial Disease (WASID)
study9 and novel treatment approaches for this disorder such as
angioplasty and stenting.10 Overall, LAICOD has been a rela-
tively neglected disorder because many have and continue to
focus on the more accessible extracranial carotid artery occlusive
disease lesion. In this commentary, we address the following
important aspects of LAICOD: (1) the magnitude of the public
health problem; (2) the risk of stroke and other cardiovascular
diseases associated with intracranial occlusive disease; (3) the
etiology; (4) medication and nonmedication approaches to treat-
ment and prevention; and (5) gaps in our understanding of
intracranial occlusive disease and possible next steps to unravel
enigmas related to this disorder.
Global Burden of Large Artery Intracranial
Occlusive Disease
LAICOD has emerged as the most common stroke subtype
worldwide as emphasized in a recently published Research
Letter in Stroke.11 In a review of the global burden of
intracranial atherosclerosis, Wong12 points out, as has
Caplan,13 for many years that only recently have clinical trials
targeted individual stroke subtypes as distinct entities rather
than indiscriminately grouping all strokes together as though
homogeneous. In relation to atherosclerotic stroke mecha-
nisms, Wong12 concludes that although extracranial large
artery atherosclerosis may be a more common lesion in
whites in Europe and America, LAICOD affecting the middle
cerebral artery, intracranial portion of the internal carotid
artery, vertebrobasilar artery, and posterior and anterior
cerebral arteries is more common in Asian patients. In fact,
LAICOD is estimated to account for 33% to 50% of stroke
and 50% of transient ischemic attack in Chinese popula-
tions; it was found in 47% of patients with stroke in Thailand;
and it was significant in approximately 48% of patients with
stroke in Singapore.12 In Korea, LAICOD is estimated to
cause up to 20% to 25% of strokes (H.J. Bae, personal
communication, December 1, 2007). In Japan, LAICOD
frequency remains high; however, extracranial carotid artery
atherosclerosis in increasing in this population. Because
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Asians have a high risk for LAICOD, which may be the same
situation for persons of Hispanic and African origin,14 and
these populations constitute an overwhelming majority of the
world’s population, LAICOD is likely the most common
vascular lesion worldwide. The Table lists the comparative
frequency of LAICOD in patients with stroke from key areas
in the world.11,12,15
Risk of Stroke and Other Cardiovascular Disease
in Large Artery Intracranial Occlusive Disease
LAICOD is associated with a high risk for ischemic stroke. In
WASID, the 2-year recurrent ischemic stroke rates were
19.7% in the aspirin treatment group and 17.2% in the
warfarin group.9 This compares with 8% to 12% in aspirin-
treated patients and 8% to 14% in warfarin-treated patients in
other recurrent stroke prevention trials.9 In the African
American Antiplatelet Stroke Prevention Study (AAASPS),
where the predominant stroke subtype at baseline among
these very high-risk patients was lacunar infarction (approx-
imately 67%), the fatal plus nonfatal recurrent stroke frequen-
cies were 11.7% for ticlopidine treatment and 9.5% for
aspirin treatment.16 In WASID, predictors of recurrent stroke
risk were stenosis 70%, recent symptoms (17 days), and
female sex.17
LAICOD may not exist in isolation as a sole atherosclerotic
occlusive lesion. Death from myocardial infarction was uncom-
mon in WASID (none in the aspirin treatment group, 3 in the
warfarin group), and the occurrence of fatal or nonfatal myocar-
dial infarction was relatively uncommon in WASID (7 in the
aspirin group, 12 in the warfarin group) among 280 patients
treated with aspirin and 289 patients treated with warfarin.9
Coronary atherosclerosis, however, may occur in association
with LAICOD. The correlation of coronary atherosclerosis in
Korean patients, however, may be stronger for extracranial
carotid atherosclerosis than LAICOD.18 Concomitant occur-
rence of LAICOD and coronary atherosclerosis should not be
unexpected because intracranial atherostenosis may be associ-
ated with aortic plaque19 and metabolic syndrome,20 factors that
may be associated with coronary atherosclerosis. The GESICA
natural history study based in France suggests both a high 2-year
recurrence rate of ischemic events in the stenotic cerebral artery
territory (38.2% with stroke accounting for 13.7% and transient
ischemic attack 24.5% of events) and cardiovascular events in
18.6% with an 8.8% vascular death rate.21
Etiology
Despite the high prevalence and importance of LAICOD, there
is a relative paucity of information about causation. Studies from
Wong’s group in Hong Kong22,23 and another study24 suggest a
possible role for diabetes mellitus, metabolic syndrome, and
other cardiovascular risk factors. Furthermore, several studies
have attempted to explain racial differences in the distribution of
extracranial and intracranial occlusive disease.1,2 Hypotheses
regarding level of raised blood pressure (predisposing to intra-
cranial occlusive disease) or elevated cholesterol (predisposing
to extracranial occlusive disease) have been applied to explain
these differences. In the international Extracranial/Intracranial
Bypass Trial, race (black, Asian) was associated with lesion
distribution in multivariate analysis.25 In the Northern Manhattan
Stroke Study, a greater occurrence of diabetes and hypercholes-
terolemia was noted among blacks and Hispanics, which ac-
counted for a major proportion of the increased frequency of
intracranial occlusive disease.26
Caplan has suggested that high blood volume states asso-
ciated with such factors as female sex (eg, during pregnancy,
menstruation), diabetes, and hypertension in blacks and
Asians may explain race–ethnic propensity for LAICOD.26
Burke and Howard provide an interesting alternative perspec-
tive on the distribution of asymptomatic extracranial athero-
sclerosis in blacks and whites whereby population studies
suggest at least an equal amount of asymptomatic extracranial
atherosclerosis in blacks and whites when measures of
intimal media thickness are taken into account.27 This may be
explained, at least in part, by younger age of stroke onset in
blacks (ie, full-blown atherosclerosis, which has been studied
at referral-based centers, is more prevalent in older age) and
different stroke subtypes such as hemorrhagic stroke related
to hypertension, which occurs at younger ages in blacks and
serves as a competing cause of mortality.
Several interesting observations have been published recen-
tly in relation to etiology and pathophysiology of LAICOD.
For example, despite the uncertainty about the etiology of
LAICOD, embolism and hypoperfusion are important factors
in causing recurrent stroke.28–30 Furthermore, age, hyperten-
sion, and diabetes mellitus have been shown to be indepen-
dent risks for asymptomatic LAICOD.31
Approaches to Treatment and Prevention
Overall, treatment and prevention of LAICOD has been unsuc-
cessful. For example, study of a low-molecular-weight heparin,
3800 IU nadroparin calcium antifactor Xa twice daily subcuta-
neously versus 160 mg oral aspirin daily for 10 days in Asian
patients with acute ischemic stroke and predominantly LAICOD
has been reported. There was no significant benefit for nadropa-
rin calcium at 6 months on the Barthel index (absolute reduction
4%; 95% CI, 5 to 13), the primary outcome measure.32 In
addition, for recurrent stroke prevention, the WASID study did
not show significant efficacy of warfarin over aspirin therapy for
LAICOD but showed an excess of hemorrhages.9 The interna-
tional Extracranial to Intracranial Bypass Trial suggested that
bypass might be deleterious for some intracranial occlusive
lesions in nonprimary analysis.8 Other agents such as cilostazol
may hold promise33 as may antihypertensive agents and choles-
terol-lowering drugs, which could merit further large-scale study
for first and recurrent stroke prevention. Revascularization and
flow augmentation with intracranial stenting and counterpulsa-
tion devices continue to be studied in this important field.10,34
Table. Comparative Frequency of LAICOD in Patients With Stroke
Ethnic Groups
Reported Frequency of LAICOD
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Intracranial revascularization with the Wingspan stent has been
approved by the US Federal Drug Administration for patients
with medically refractive LAICOD.
Gaps and Next Steps
LAICOD is a major worldwide stroke problem that we cannot
ignore. It seems to be the most common stroke subtype and
will likely become an even more important public health
problem if the world population expands in developing regions
where LAICOD is prevalent. The etiology of LAICOD re-
mains poorly defined. Important but limited epidemiological
studies have been undertaken to better understand mecha-
nisms of LAICOD. A more precise elucidation of pathophys-
iological mechanisms leading to LAICOD would be a major
advance in our quest for prevention and treatment of this
disorder. LAICOD is subject to progression that is associated
with increased risk of cerebrovascular events.31,35
It is again time to consider pooling our collective knowledge
to form international collaborations to better study and define
LAICOD so that we can develop new therapies and better use
existent medications and devices to treat and prevent LAICOD.2
International epidemiological efforts may take the form of
hypothesis-driven collaborative registries for LAICOD and
population- or cohort-based regional comparisons to better
understand risk factors. This comparative approach may focus
on the possible role of traditional cardiovascular risk factors,
genetic factors, and other potential novel factors in conferring
risk of first and recurrent stroke. In addition, international
collaborative clinical trials should be considered or continued to
test medications that control risk factors suspected of causing
LAICOD and devices that may improve risk of first or recurrent
stroke in conjunction with LAICOD. Because the intracranial
and extracranial arteries differ structurally, there may be oppor-
tunities for basic studies to open up new avenues for treatment
and prevention.26 A collaborative international basic science
approach is warranted to elucidate new mechanisms to target for
prevention and treatment of LAICOD, a disorder that is far
reaching worldwide.36
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